Non-small Cell Lung Cancer (NSCLC) Clinical Trials in Tampa, Florida

8 studies are recruiting for non-small cell lung cancer (nsclc) in Tampa, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

   This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   20 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07277413 on ClinicalTrials.gov

2. Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

   TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Tampa, Florida

   Locations

   206 in total

   Run by

   AstraZeneca

   See if you can join NCT07291037 on ClinicalTrials.gov

3. Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

   This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active dru…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Moffitt Cancer Center and Research Institute, Tampa, Florida

   Locations

   74 in total

   Run by

   Genmab

   See if you can join NCT07288177 on ClinicalTrials.gov

4. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

   This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #8, Tampa, Florida

   Locations

   122 in total

   Run by

   Exelixis

   See if you can join NCT05176483 on ClinicalTrials.gov

5. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

   This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center and Research Institute, Tampa, Florida

   Locations

   55 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06128551 on ClinicalTrials.gov

6. Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

   The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subpro…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

   Locations

   93 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06162221 on ClinicalTrials.gov

7. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

   This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Lee Moffitt Cancer Center, Tampa, Florida

   Locations

   17 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06040541 on ClinicalTrials.gov

8. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

   Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   21 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT05379985 on ClinicalTrials.gov